Trump Contemplates Reclassifying Marijuana in the U.S.

Post by : Raina Nasser

President Donald Trump has shared that his administration is seriously evaluating the potential to ease federal regulations on marijuana by reclassifying it as a drug of lesser danger. This could represent a significant shift in the federal government’s entrenched stance toward marijuana laws in the U.S.

In remarks made to reporters on Monday, Trump indicated that talks are ongoing about altering marijuana's current classification under federal law. When questioned about the possibility of an executive order regarding marijuana reclassification, Trump affirmed that the prospect is indeed under serious review by his team.

The President highlighted that many support the reclassification of marijuana, as its existing legal status hinders scientific exploration. He pointed out that stringent federal regulations prevent comprehensive studies on marijuana, suggesting that reclassification could pave the way for more medical and scientific inquiries in the future.

Currently, marijuana is designated as a Schedule I substance federally. This classification is reserved for drugs deemed to have a high potential for abuse and no widely acknowledged medical use, with heroin and LSD falling into this category. Consequently, marijuana is subjected to the most stringent federal controls.

Despite this federal classification, marijuana-related laws differ significantly across states. Numerous states have opted to legalize medical marijuana, and many allow recreational use. In total, 24 states and Washington, D.C., permit small quantities of marijuana for recreational purposes, underscoring the growing disparity between state regulations and federal policy.

Reports indicate that President Trump is likely to advocate for marijuana to be reclassified to Schedule III, which includes substances acknowledged to have medical value with a lower risk of dependency. Drugs like ketamine and anabolic steroids are examples of Schedule III substances.

Reclassifying marijuana would not equate to full legalization or decriminalization at the federal level. However, it would substantially ease restrictions. Experts assert this could lead to simplified clinical research processes, as Schedule I drugs necessitate extensive approvals before research can commence.

This change could also yield significant economic benefits for the legal cannabis sector. Businesses legally cultivating and selling marijuana might enjoy lower taxes and reduced regulatory burdens if it is reclassified.

Importantly, the U.S. President lacks unilateral authority to effectuate drug reclassification. Any modification requires formal action from federal agencies. Reports suggest Trump intends to sign an executive order instructing these agencies to initiate the reclassification procedure.

The question of marijuana reclassification isn’t novel. The previous administration had also looked into amending marijuana's federal classification but did not finalize the process before Trump assumed office in early 2025.

The United States maintains a fragmented landscape of marijuana laws, with each state determining its own rules around possession, cultivation, and sales. Trump’s statements signify a potential shift in federal marijuana policy that may align more closely with the laws established by many states.

If pursued, reclassifying marijuana could emerge as one of the most impactful drug policy revisions in recent years, with extensive repercussions for research, business, and federal enforcement.